This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

GLP-2 (Glucagonlike Peptide-2) and Blood Flow

This study has been completed.
Information provided by:
Glostrup University Hospital, Copenhagen Identifier:
First received: October 4, 2007
Last updated: February 10, 2011
Last verified: October 2007

It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put.

GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure.

The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).

Condition Intervention
Regional Blood Flow Other: Glucagonlike peptide

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Role of GLP-2 in Univercal Changes in Blood Flow in Humans

Further study details as provided by Glostrup University Hospital, Copenhagen:

Primary Outcome Measures:
  • effect of glp-2 [ Time Frame: during study ]

Secondary Outcome Measures:
  • potential new ideas for further studies [ Time Frame: months to years ]

Enrollment: 15
Study Start Date: October 2007
Study Completion Date: February 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
450 nmol GLP-2 SC
Other: Glucagonlike peptide
450 nmol native form, synthetic
Placebo Comparator: 2
1 ml isotonic saline SC
Other: Glucagonlike peptide
450 nmol native form, synthetic

Detailed Description:
se the above

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 20-60
  • Healthy
  • No medication
  • Not pregnant

Exclusion Criteria:

  • All of the persons not meeting the abowe mentioned criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00540215

Glostrup University Hospital
Glostrup, Region Hovedstaden, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
Principal Investigator: lasse bremholm, MD Glostrup university hospital
  More Information Identifier: NCT00540215     History of Changes
Other Study ID Numbers: H-D-2007-0050
Study First Received: October 4, 2007
Last Updated: February 10, 2011 processed this record on August 22, 2017